The Conversation (0)
SEER, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY.
Seer's management is scheduled to participate in a fireside chat on Tuesday, September 9 th at 12:20 p.m. Eastern Time / 9:20 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the conference.
About Seer
SEER, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed, precision, and reproducibility previously unattainable. SEER's Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges that conventional methods have failed to overcome. Traditional proteomic technologies have historically struggled with inconsistent data, limited throughput, and prohibitive complexity, but SEER's robust and scalable workflow consistently reveals biological insights that others do not. SEER's products are for research use only and are not intended for diagnostic procedures. For more information about SEER's differentiated approach and ongoing leadership in proteomics, visit www.seer.bio .
Media Contact:
Consort Partners
pr@seer.bio
Investor Inquiries:
Carrie Mendivil
investor@seer.bio
